Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study-Reference-Cited by-同舟云学术

Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study

Published:2017-02-26 Issue:13 Volume:8 Page:21903-21917
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Duruisseaux Michaël¹,Besse Benjamin²,Cadranel Jacques³,Pérol Maurice⁴,Mennecier Bertrand⁵,Bigay-Game Laurence⁶,Descourt Renaud⁷,Dansin Eric⁸,Audigier-Valette Clarisse⁹,Moreau Lionel¹⁰,Hureaux José¹¹,Veillon Remi¹²,Otto Josiane¹³,Madroszyk-Flandin Anne¹⁴,Cortot Alexis¹⁵,Guichard François¹⁶,Boudou-Rouquette Pascaline¹⁷,Langlais Alexandra¹⁸,Missy Pascale¹⁹,Morin Franck¹⁹,Moro-Sibilot Denis¹

Affiliation:

1. Centre Hospitalier Universitaire Grenoble Alpes, Thoracic Oncology Unit, Chest Department, Grenoble, France

2. Medical Oncology Department, Gustave Roussy, Villejuif, France

3. Assistance Publique Hôpitaux de Paris, Tenon Hospital, Chest Department, Paris, France

4. Léon-Bérard Cancer Center, Lyon, France

5. Centre Hospitalier Universitaire de Strasbourg, Chest Department, Strasbourg, France

6. Larrey Hospital, Chest Department, Toulouse, France

7. Centre Hospitalier Universitaire de Brest, Brest, France

8. Oscar Lambret Cancer Center, Medical Oncology Department, Lille, France

9. Centre Hospitalier Sainte Musse, Chest Department, Toulon, France

10. Centre Hospitalier Général de Colmar, Louis Pasteur Hospital, Chest Department, Colmar, France

11. Centre Hospitalier Universitaire d’Angers, Chest Department, Angers, France

12. Centre Hospitalier Universitaire de Bordeaux, Respiratory Disease Department, Pessac, France

13. Antoine Lacassagne Cancer Center, Nice, France

14. Paoli Calmettes Institute, Marseille, France

15. Centre Hospitalier Universitaire de Lille, Thoracic Oncology Unit, Lille, France

16. Medical Oncology Department, Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France

17. Assistance Publique Hôpitaux de Paris, Cochin-Port Royal Hospital, Medical Oncology Department, Paris, France

18. French Cooperative Thoracic Intergroup, Department of Biostatistics, Paris, France

19. French Cooperative Thoracic Intergroup, Clinical Research Unit, Paris, France

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 140 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New Benchmark for Targeted Therapies in Lung Cancer: Median Progression-Free Survival for Lorlatinib in Advanced ALK+ Non–Small Cell Lung Cancer Surpasses 5 years;Journal of Clinical Oncology;2024-09-04

2. Real-World Treatment and Outcomes in ALK-Rearranged NSCLC: Results From a Large U.S.-Based Database;JTO Clinical and Research Reports;2024-08

3. Pathways and targeting avenues of BRAF in non-small cell lung cancer;Expert Opinion on Therapeutic Targets;2024-07-02

4. Current status of molecular diagnostics for lung cancer;Exploration of Targeted Anti-tumor Therapy;2024-06-27

5. Lorlatinib in the second line and beyond for ALK positive lung cancer: real-world data from resource-constrained settings;BJC Reports;2024-05-01